Comparison of Chemotherapeutic Regimens Frequently Used in Metastatic Non-squamous NSCLC Treatment
| العنوان: | Comparison of Chemotherapeutic Regimens Frequently Used in Metastatic Non-squamous NSCLC Treatment |
|---|---|
| المؤلفون: | Magda Barinova, Jana Skrickova, P. Opálka, Miloš Pešek, M. Černovská, Martin Safanda, Karolina Hurdalkova, Helena Coupkova, Martin Svaton, Daniel Krejci, Milada Zemanova, Monika Bratová, Michal Hrnčiarik, Daniel Dolezal, J. Krejčí, Petra Zemanova, Leona Koubková, Juraj Kultan, Ondrej Fischer |
| المصدر: | Anticancer Research. 41:2597-2603 |
| بيانات النشر: | Anticancer Research USA Inc., 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Male, Oncology, Cancer Research, medicine.medical_specialty, Paclitaxel, Bevacizumab, medicine.medical_treatment, Population, Pemetrexed, chemistry.chemical_compound, Carcinoma, Non-Small-Cell Lung, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Neoplasm Metastasis, education, Immune Checkpoint Inhibitors, Aged, Aged, 80 and over, Chemotherapy, education.field_of_study, business.industry, Cancer, General Medicine, Middle Aged, medicine.disease, Progression-Free Survival, 3. Good health, Regimen, chemistry, Non squamous, Female, business, medicine.drug |
| الوصف: | Background/aim Platinum-based chemotherapy with pemetrexed or paclitaxel/bevacizumab are regimens used in combination with checkpoint inhibitors in non-squamous non-small cell lung cancer (NSCLC) treatment. We conducted a real-world study to compare the outcomes of these chemotherapeutic regimens. Patients and methods We investigated 1,534 patients with advanced non-squamous NSCLC treated with platin/pemetrexed (n=1212) or platin/paclitaxel/bevacizumab (n=322) in 9 cancer centres in the Czech Republic. Results The regimen containing platin/paclitaxel/bevacizumab showed significantly better overall response rate (ORR) compared to the platin/pemetrexed [40.8% vs. 32.7% (p=0.008)] in the overall population and [55.0% vs. 38.8% (p=0.002)] in the Eastern Cooperative Oncology Group performance status 0 group. There was no significant improvement in progression-free survival (PFS) and overall survival (OS) in either of these two groups of patients. Conclusion In our real-world data analysis, patients treated with platin/paclitaxel/bevacizumab had better overall response rate (ORR), but not PFS or OS. Thus, both treatment regimens are similarly effective. Their selection should therefore be based on the potential side effects. |
| تدمد: | 1791-7530 0250-7005 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::057bcac6de29fe9f3a3ce1185eafb469 https://doi.org/10.21873/anticanres.15039 |
| رقم الأكسشن: | edsair.doi.dedup.....057bcac6de29fe9f3a3ce1185eafb469 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 17917530 02507005 |
|---|